3.47

1.76% 0.06

After Hours: 3.47

Arbutus Biopharma Corp (ABUS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arbutus Biopharma Corp stock is traded at $3.47, with a volume of 470.82K. It is up +1.76% in the last 24 hours and down -12.59% over the past month. Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Previous Close:

$3.41

Open:

$3.45

24h Volume:

470.82K

Relative Volume:

0.44

Market Cap:

$643.75M

Revenue:

$12.99M

Net Income/Loss:

$-74.39M

P/E Ratio:

-7.5435

EPS:

-0.46

Net Cash Flow:

$-78.92M

1W Performance:

+0.87%

1M Performance:

-12.59%

6M Performance:

+5.47%

1Y Performance:

+88.59%

1-Day Range:

$3.385

$3.50

1-Week Range:

$3.385

$3.58

52-Week Range:

$1.79

$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name

Arbutus Biopharma Corp

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

604-419-3200

Address

701 VETERANS CIRCLE, WARMINSTER, PA

Employee

Twitter

@arbutusbio

Next Earnings Date

2024-11-06

Latest SEC Filings

ABUS's Discussions on Twitter

Compare ABUS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABUS Arbutus Biopharma Corp	3.47	643.75M	12.99M	-74.39M	-78.92M	-0.46
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Initiated	Jefferies	Hold
Dec-17-20	Initiated	H.C. Wainwright	Buy
Jul-27-20	Resumed	JMP Securities	Mkt Outperform
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-20-20	Initiated	Robert W. Baird	Outperform
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Oct-07-19	Reiterated	B. Riley FBR	Buy
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral
Oct-12-18	Reiterated	Chardan Capital Markets	Buy
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Mar-19-18	Resumed	Chardan Capital Markets	Buy
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-01-17	Reiterated	Wedbush	Outperform
Dec-13-16	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-30-16	Upgrade	Chardan Capital Markets	Neutral → Buy

View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

Nov 27, 2024

Principal Financial Group Inc. Reduces Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Nov 27, 2024

Nov 25, 2024

Arbutus Biopharma (FRA:I9DN) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com

Nov 25, 2024

Nov 22, 2024

Arbutus Biopharma (STU:I9DN) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Arbutus Biopharma (STU:I9DN) Long-Term Debt & Capital Lease Obligation : €0.88 Mil (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024

Nov 20, 2024

Arbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan Capital - MarketBeat

Nov 20, 2024

Nov 18, 2024

HC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat

Nov 18, 2024

Nov 17, 2024

Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment - MyChesCo

Nov 17, 2024

Promising New Data from Hepatitis B Trial by Arbutus and Barinthus - MyChesCo

Nov 17, 2024

Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World

Nov 17, 2024

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in October - Defense World

Nov 17, 2024

Nov 16, 2024

ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo

Nov 16, 2024

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat

Nov 16, 2024

Nov 15, 2024

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Two Seas Capital LP Adjusts Stake in Arbutus Biopharma Corp - GuruFocus.com

Nov 14, 2024

Arbutus to Present at Jefferies London Healthcare Conference - Yahoo Finance

Nov 14, 2024

Nov 12, 2024

Creative Planning Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Nov 12, 2024

Nov 11, 2024

HC Wainwright Has Negative Forecast for ABUS FY2024 Earnings - MarketBeat

Nov 11, 2024

HC Wainwright Expects Weaker Earnings for Arbutus Biopharma - Defense World

Nov 11, 2024

Nov 09, 2024

HC Wainwright Reaffirms “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World

Nov 09, 2024

Nov 08, 2024

Arbutus Biopharma 8-K Filing: Financial Results and Corporate Presentation Update - Defense World

Nov 08, 2024

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

JMP Securities Increases Arbutus Biopharma (NASDAQ:ABUS) Price Target to $5.00 - Defense World

Nov 08, 2024

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World

Nov 08, 2024

Nov 07, 2024

HC Wainwright Reaffirms Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat

Nov 07, 2024